Sclerotherapy Market Size, Share, Growth – By Agents, By Therapy, By Application, Global Forecast, 2025 – 2034

Sclerotherapy Market Size

The global sclerotherapy market size was valued at USD 1.3 billion in 2024 and is projected to exhibit 6.1% CAGR from 2025 - 2034. Emerging prevalence of vascular diseases, growing desire for non-invasive therapeutic services, approval of new sclerosant agents, and increased sclerotherapy use as an inexpensive index procedure for surgery are contributing to the revenue expansion of the market.
 

Patients that would traditionally require surgery to treat vascular conditions now prefer to undergo sclerotherapy procedures. This procedure is simple and can be performed on an outpatient basis without the use of general anesthesia, which lessens associated risks with surgery and provides patients with a quicker and easier recovery option. For instance, patients who wish to treat varicose veins using sclerotherapy can expect to pay between USD 300 and 500, while surgery options like ambulatory phlebectomy will cost USD 2000–4000. It is clear why many patients tend to the less invasive option of sclerotherapy than traditional surgery, contributing positively to the world market.
 

Sclerotherapy is a minimally invasive procedure that involves the treating of the affected veins using an injection of sclerosing solution or foam into the targeted vein. As a result, the affected vein collapses and sticks together, after which it is gradually replaced with scar tissue and eventually gets absorbed.
 

Sclerotherapy Market Trends

Several key trends, driven by technological advancements, patient preferences, and evolving healthcare delivery, are shaping the growth and development of the market.
 

• In sclerotherapy, Artificial Intelligence (AI) is making a shift by offering smarter diagnostic and treatment methodologies. Medical practitioners analyze the structure of the veins and find the best locations for injection using AI-based imaging systems. This has led to improved variability among practitioners and better treatment outcomes. Furthermore, AI-aided tools are now being used for post-treatment recovery monitoring, complication detection, and long-term outcome enhancement.
   
• The integration of laser treatment and sclerotherapy has gained wide acceptance for medium and large venous conditions. Medical-grade lasers treat smaller veins while sclerotherapy treats larger veins. This combination improves effectiveness and reduces the number of procedures required since one method supports the other. This approach is particularly advantageous to patients who expect extensive vein treatment and wish to recover quicker and achieve superior aesthetic results.
   
• There is an increasing interest to adopt robotic systems to increase the efficacy of sclerotherapy globally. The process of injecting the sclerosant is automated with the use of robotic systems, which makes certain that the accurate volume is injected in an appropriate place. This minimizes the errors made and guarantees improved results.
   
• On the other hand, the industry is also developing the robotic systems to be operated remotely or for full automation in the treatment procedures, which comes in handy in intricate or large-scale operations.
   
• In addition, the 3D medical imaging devices are assisting the doctors in generating accurate representations of the patient's venous system for effective treatment procedures.
   
• With regard to complex cases, the technology works best in helping to find concealed or not easily reachable veins. 3D imaging delivers a clear insight into the vein structure, which guarantees the accurate administering of the sclerosant, therefore, increasing the effectiveness of the treatment.
   

Sclerotherapy Market Analysis

Based on agents, the market is segmented into detergents, chemical irritants, and osmotic agents. Detergents segment dominates the market with a share of 68.1% in 2024.
 

• In comparison to other types of sclerosing agents, detergents such as polidocanol and sodium tetradecyl sulfate are deemed superior due to their safety profile and effectiveness. These products lead the market as they can be used for cosmetic purposes and medical treatment for spider and varicose veins.
   
• It is a well-known fact that these agents are used widely because they have obtained approval from regulatory bodies which include the U.S. FDA.
   
• Polidocanol detergent, a sodium ester, will have a lower risk of allergic complications and hyperpigmentation compared to osmolytic agents and chemical irritants.
   

Based on therapy, the sclerotherapy market is segmented into liquid sclerotherapy, ultrasound sclerotherapy, foam sclerotherapy, and other therapies. Liquid sclerotherapy segment dominates the market with a share of 46.9% in 2024.
 

• Liquid sclerotherapy dominates due to its versatility, cost-effectiveness, and suitability for treating smaller veins like spider veins. And compared with foam-based or other advanced treatments, it is no contest, it costs much less. This ensures patients and clinics on a budget can make use of it.
   
• Additionally, specialists are finding it to be a safer strategy for smaller veins because there is less chance of complications like embolization. Also, it is a basic and uncomplicated procedure that does not need much preparation like foam or other therapies.
   

Based on application, the sclerotherapy market is segmented into varicose veins, hemorrhoids, malformed lymph vessels, hydroceles, and other applications. The varicose veins segment held a dominating share of 64.8% in the market in 2024.
 

• Some major demographics affected by varicose veins include elderly poorly mobile individuals, pregnant women, and people who work in manual labor jobs or who are sedentary. Multidisciplinary Digital Publishing Institute conducted a study in December of 2023 which showed that between 10% to 30% of the entire world population has lower limbs varicose veins. The disorder spread globally has fostered a higher demand for effective treatments like sclerotherapy.
   
• Moreover, the demand for sclerotherapy as a means of treating varicose veins has grown thanks to the increased interest in new treatment methods by patients. Such methods include minimally invasive surgery which allows quicker recoveries and lower levels of pain compared to traditional methods.
   

In 2024, the U.S. led the North American sclerotherapy market, generating a revenue of about USD 483 million.
 

• The market is experiencing growth due to a driving factor which is the high prevalence of sclerovascular disorders in the U.S.; According to the 2024 varicose vein's statistics released by the Chicago Vein Institute, more than half (50%) of the population above 50 years of age in the U.S. is estimated to be suffering from Superficial Venous Disease which increases the need for sclerotherapy treatment as well as other related services.
   
• Moreover, sclerotherapy is performed in the U.S. because there are properly established healthcare institutions along with specialized clinics and hospitals to carry out the procedures, and there are sophisticated diagnostic technologies available such as ultrasound which boosts the efficacy of treatment provided.
   

The UK is set to see a robust expansion in its sclerotherapy market from 2025 - 2034.
 

• The market in the UK is expanding because there is more awareness about treatment methods that do not require incisions to treat vascular diseases. A July 2022 Report authored by the National Center for Biotechnology Information has indicated that endovenous sclerotherapy has increased by 60 percent from the years 2006 to 2021 while surgical procedures have decreased.
   
• Also, health campaigns in the UK through the NHS Long Term Plan, in particular, are seeking to support patients by encouraging proactive sclerotherapy, thereby increasing the patient population seeking different treatment options.
   

Japan's sclerotherapy market is set for lucrative growth from 2025 to 2034.
 

• The prevalence of therapies like sclerotherapy for venous diseases is facilitated by the combination of Japan’s sophisticated healthcare infrastructure and progressive broadening healthcare access.
   
• According to the World Bank Group, as of 2023, around 30% of the Japanese population is aged 65 and above, resulting in the growth of the nation’s age-related problems such as varicose veins to grow.
   
• Therefore, the need for sclerotherapy, which is a less invasive procedure, has increased in the region.
   

Saudi Arabia's sclerotherapy market is expected to witness substantial growth during the forecast period.
 

• The sclerotherapy treatment demand is expected to increase because Saudi Arabia is investing substantially into its healthcare system, which is coupled with the increasing incidence of venous disorders like varicose veins.
   
• Pregnancy, obesity, and insufficient physical activities all contribute to the increase in venous disorders in the country. In May 2024, the National Center for Biotechnology Information published a study on the prevalence of varicose veins in Saudi Arabia and found it to be 62%, which consequently resulted in strong demand for sclerotherapy treatments.
   

Sclerotherapy Market Share

The sclerosant market is highly diffuse because it includes multiple players from different segments, such as manufacturers, clinical providers, and specialized clinics, which leads to a positive scenario for competition. The fragmentation is a result of a massive variety of products, technologies, and approaches to dealing with venous abnormality disorders. Well-known brands usually have a broad range of products and operate in many countries. However, other smaller firms tend to focus on markets that are not as competitive and could benefit from novel products.
 

USPs of Sclerotherapy Market

• Proven solution for varicose and spider veins.
• Quick, non-surgical procedure with minimal downtime.
• Enhances appearance and boosts confidence.
• Suitable for various vein-related conditions.
   

Sclerotherapy Market Companies

Some of the eminent market participants operating in the sclerotherapy industry include:

• AngioDynamics
• Bioniche Pharma Group
• Boston Scientific Corporation
• Changan Tianyu group
• Chemische Fabrik Kreussler 
• Cook Medical
• Endo-Flex (Meditek Systems)
• Erbe Elektromedizin
• LGM Pharma
• Medtronic
• MTW ENDOSKOPIE
• Omega Labs
• Perrigo Company
• Samarth Life Sciences
• Troikaa Pharmaceuticals
   

Sclerotherapy Industry News:

• In December 2023, Chemische Fabrik Kreussler announced a partnership with S.T.D. Pharmaceutical Products to globally produce, market, and distribute Fibrovein. S.T.D. Pharmaceutical Products sought a strategic partner to achieve their goal of increased productive and marketing competition for Fibrovein in the sclerotherapy field.
   

The sclerotherapy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Agents

• Detergents
• Chemical irritants
• Osmotic agents

Market, By Therapy

• Liquid sclerotherapy
• Ultrasound sclerotherapy
• Foam sclerotherapy
• Other therapies

Market, By Application

• Varicose veins
• Hemorrhoids
• Malformed lymph vessels
• Hydroceles
• Other applications

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE